GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of FLOW got published and nobody in here is talking about eGFR slope — 30 comments in the full submission. View in context.
287
c/trialwatch·submitted 3 days ago by u/ines_castellanos

FLOW got published and nobody in here is talking about eGFR slope

Paperbranch of 5 comments

Quick one. Canada here. endpoint works very differently where I live than in the threads that dominate the front page, and I keep seeing people confidently given advice that simply does not apply outside the US. Specifics: the route I used took 20 weeks and cost roughly what I expected. The admin was worse than the…

Read the full submission and all 30 comments →

This branch

5 comments, started 2 days ago
u/nightowl_injector15 points·2 days ago

Mechanistically the bit that matters is SELECT. It explains most of the early profile and a decent chunk of the outcome.

replysharereportpermalink
u/ines_castellanosOP9 points·1 days ago

Phase 2 TRIUMPH looked amazing. Phase 3 trials are harder. Do not anchor on phase 2 readouts.

replysharereportpermalink
u/cesar_ivaturi0 points·1 days ago

absolute risk reduction, not relative risk reduction, that is how you decide

replysharereportpermalink
u/rina_bergstrom0 points·1 days ago

number-needed-to-treat is the house dialect

replysharereportpermalink
u/renal_outcomes_rnephro-curious8 points·1 days ago

Mechanistically the bit that matters is SELECT.

Disagree on that part. 99.2% and 99.2% on the same vial is normal.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →